Jasper Therapeutics director buys preferred shares
Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., acquired 888.0000 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 through a private placement under a securities purchase agreement.
Rhea-AI Filing Summary
Patrick J. Crutcher, a director of Jasper Therapeutics, Inc., acquired 888.0000 shares of Non-Voting Convertible Preferred Stock on July 20, 2026 through a private placement under a securities purchase agreement. After stockholder approval, each preferred share will automatically convert into 61 shares of Voting Common Stock, subject to a beneficial ownership cap between 4.9% and 19.9%. Crutcher was also granted stock options for 15000.0000 shares of Voting Common Stock at a $0.7740 exercise price, vesting 25% after one year and monthly over the following 36 months, contingent on continued service.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 888 shares
Net Buy
2 txns
Insider
Crutcher Patrick J
Role
Director
Bought
888 shs
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Non-Voting Convertible Preferred Stock F2, F3 | 888 | -- | -- |
| Grant/Award | Stock Option (Right to Buy F1 | 15,000 | $0.00 | $0.00 |
Holdings After Transaction:
Stock Option (Right to Buy — 15,000 contracts (Direct);
Non-Voting Convertible Preferred Stock — 888 contracts (Direct)
Footnotes (3)
- F1. The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date.
- F2. On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026.
- F3. On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date.
Key Figures
Preferred shares acquired: 888.0000 shares
Stock options granted: 15000.0000 shares
Option exercise price: $0.7740 per share
+2 more
5 metrics
Preferred shares acquired
888.0000 shares
Non-Voting Convertible Preferred Stock acquired on July 20, 2026 in a private placement
Stock options granted
15000.0000 shares
Stock options for Voting Common Stock granted on July 16, 2026
Option exercise price
$0.7740 per share
Exercise price for 15000.0000 stock options awarded to the director
Conversion ratio
61 shares
Each preferred share converts into 61 shares of Voting Common Stock after stockholder approval
Beneficial ownership cap
4.9% to 19.9%
Holder-selected maximum ownership percentage after conversion of preferred shares
Key Terms
Non-Voting Convertible Preferred Stock, securities purchase agreement, private placement, beneficially own, +1 more
5 terms
Non-Voting Convertible Preferred Stock financial
"Acquisition of Non-Voting Convertible Preferred Stock in private placement"
A non-voting convertible preferred stock is a share that normally pays a fixed dividend and takes priority over common stock for payouts, but does not grant the holder the right to vote on corporate matters. It can be exchanged later for a set number of common shares, offering the potential to participate in price gains without immediate control—like holding a high-yield loan that can be turned into equity, which matters to investors weighing steady income, upside potential, and possible dilution of ownership.
securities purchase agreement financial
"Issuer entered into a securities purchase agreement with accredited investors"
A securities purchase agreement is a written contract between a buyer and a seller outlining the terms for buying or selling financial assets such as stocks or bonds. It specifies details like the price, quantity, and conditions of the transaction, similar to a shopping list with agreed-upon terms. For investors, it provides clarity and legal protection when transferring ownership of these financial instruments.
private placement financial
"Preferred stock was issued and sold in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
beneficially own financial
"Holder cannot convert if it would beneficially own above a set percentage"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Voting Common Stock financial
"Preferred stock converts into shares of the Issuer's Voting Common Stock"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transactions did Jasper Therapeutics (JSPR) report for Patrick J. Crutcher?
Jasper Therapeutics reported that director Patrick J. Crutcher acquired 888.0000 preferred shares in a private placement and received stock options for 15000.0000 shares of Voting Common Stock. The preferred shares are convertible and the options carry a defined vesting schedule.
What are the key terms of the stock options granted to the Jasper Therapeutics (JSPR) director?
The director received stock options for 15000.0000 shares of Voting Common Stock at a $0.7740 exercise price. 25% vest on the one-year anniversary of grant, with the remainder vesting in equal monthly installments over the next 36 months, subject to continuous service.
Was the Jasper Therapeutics (JSPR) director’s purchase made through a private placement?
Yes. The issuer entered a securities purchase agreement with accredited investors, including the director, and issued the 888.0000 preferred shares in a private placement that closed on July 20, 2026, according to the disclosure footnotes.
Are the Jasper Therapeutics (JSPR) insider transactions under a Rule 10b5-1 trading plan?
No. The Rule 10b5-1 checkbox for the reported transactions is not marked, and the footnotes describe a negotiated private placement and an option grant, rather than trades executed under a pre-arranged Rule 10b5-1 trading plan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
